Plain-English translation of NCT05855200 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new immunotherapy medicine, in people with stage III colon cancer that has specific genetic features (called dMMR or MSI-H). You would receive this medication before surgery to remove the cancer, then continue receiving it after surgery. The researchers want to see if this approach works better than the standard treatments (chemotherapy or simply watching and waiting) that doctors typically use.
Standard treatments for advanced colon cancer don't work well for everyone, and some people experience serious side effects. Researchers believe this medication might help the immune system fight colon cancer more effectively, especially in tumors with these particular genetic markers, potentially improving outcomes and quality of life.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or standard care. If assigned to the medication group, you would receive infusions before your surgery and then continue receiving them after surgery over a period of time. If assigned to the standard care group, you would either receive standard chemotherapy or be monitored closely without additional treatment. Throughout the trial, you would have regular clinic visits, blood tests, and imaging scans to monitor how you are doing and whether the treatment is working.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States